A Decade of Transformation in Melanoma Treatments

A Decade of Transformation in Melanoma Treatments

Publication date: May 24, 2022

The trials that led to the approval showed an overall response rate (ORR) of just 10. 9% in patients with previously treated advanced melanoma, but the toxicity was severe. (The drug was also later approved as first-line monotherapy in patients whose melanoma expresses high levels of PD-L1. 17) Grade 3 or 4 immune-related adverse events (AEs) occurred in 10% to 15% of patients who received ipilimumab, and more than 2% of study patients suffered treatment-related deaths. The first was the enthusiasm that physicians like Flaherty had for directing patients away from approved treatments and toward trials. Pembrolizumabs accelerated approval was based on a 26% ORR in 173 patients with melanoma in the phase 1 KEYNOTE-001 study (NCT01295827). The PFS rate at 12 months was 47. 7% in the co bination group vs 36. 0% in the monotherapy group. Median PFS was only 5. 3 months because tumors developed resistance to treatment through MAP kinase reactivation.

Concepts Keywords
Academic Chemotherapy
Chemotherapy Ipilimumab
Gp100 Nivolumab
Massachusetts Melanoma
Cancer treatments
Antineoplastic drugs
Bristol-Myers Squibb
Clinical medicine
Orphan drugs
Breakthrough therapy
Triplet combination
Relatlimab nivolumab
Melanoma Treatment


Type Source Name
drug DRUGBANK Atezolizumab
drug DRUGBANK Binimetinib
drug DRUGBANK Encorafenib
drug DRUGBANK Cobimetinib
drug DRUGBANK Trametinib
drug DRUGBANK Dabrafenib
disease MESH death
drug DRUGBANK Vemurafenib
drug DRUGBANK Talimogene laherparepvec
disease MESH brain metastases
disease MESH community
drug DRUGBANK Pembrolizumab
drug DRUGBANK Nivolumab
pathway REACTOME Immune System
drug DRUGBANK Ipilimumab
drug DRUGBANK Tropicamide
disease MESH Cancer
drug DRUGBANK Dacarbazine
pathway KEGG Melanoma
disease MESH Melanoma

Original Article

Leave a Comment

Your email address will not be published.